Meridian Bioscience VIVO
$ 33.97
0.0%
Quarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Balance Sheet 2011-2024 | VIVO
Annual Balance Sheet Meridian Bioscience
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-54.6 M | 12.2 M | 17.1 M | 13.4 M | -9.58 M | -2.42 M | 11.1 M | -50 M | -43 M | -44.3 M | -31.6 M | -23.6 M |
Long Term Debt |
25 M | 60 M | 68.8 M | 75.8 M | 44.9 M | 50.1 M | 54.6 M | - | - | - | - | - |
Long Term Debt Current |
1.83 M | 1.99 M | 1.79 M | - | 5.25 M | 4.5 M | 3.75 M | - | - | - | - | - |
Total Non Current Liabilities |
37.1 M | 74.3 M | 105 M | 114 M | 51.8 M | 57.3 M | 62.8 M | 2.16 M | 2.16 M | - | 171 K | 1.7 M |
Total Current Liabilities |
58 M | 47.2 M | 52.5 M | 20.9 M | 24.2 M | 22.9 M | 22.6 M | 15.3 M | 13.7 M | 21.7 M | 18.5 M | 15.3 M |
Total Liabilities |
- | - | - | 135 M | 76 M | 80.2 M | 85.4 M | 17.4 M | 15.9 M | 21.7 M | 18.6 M | 17 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
223 M | 181 M | 109 M | 63.1 M | 49.6 M | 46.9 M | 49.6 M | 51.1 M | 48.9 M | 46.9 M | 40.2 M | 38.1 M |
Total Assets |
463 M | 450 M | 405 M | 325 M | 251 M | 250 M | 252 M | 183 M | 177 M | 177 M | 161 M | 155 M |
Cash and Cash Equivalents |
81.5 M | 49.8 M | 53.5 M | 62.4 M | 59.8 M | 57.1 M | 47.2 M | 50 M | 43 M | 44.3 M | 31.6 M | 23.6 M |
Book Value |
463 M | 450 M | 405 M | 191 M | 175 M | 170 M | 166 M | 166 M | 161 M | 155 M | 143 M | 139 M |
Total Shareholders Equity |
368 M | 328 M | 248 M | 191 M | 175 M | 170 M | 166 M | 166 M | 161 M | 155 M | 143 M | 139 M |
All numbers in USD currency
Quarterly Balance Sheet Meridian Bioscience
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
25 M | 25 M | - | 25 M | 50 M | 60 M | 50 M | 60 M | 58.8 M | 68.8 M | 68.8 M | 68.8 M | 75.8 M | 75.8 M | 75.8 M | 75.8 M | 43.4 M | 44.9 M | 44.9 M | 44.9 M | 49 M | 50.1 M | 50.1 M | 50.1 M | 53.5 M | 54.6 M | 54.6 M | 54.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
37.6 M | 37.1 M | - | 40.7 M | 63.5 M | 74.3 M | 87.7 M | 74.3 M | 91.2 M | 105 M | 105 M | 105 M | 106 M | 114 M | 114 M | 114 M | 50.5 M | 51.8 M | 51.8 M | 51.8 M | 55.6 M | 57.3 M | 57.3 M | 57.3 M | 63.3 M | 63 M | 62.8 M | 62.8 M | 2.13 M | 2.16 M | 2.16 M | 2.16 M | 2.04 M | 2.16 M | 2.16 M | 2.16 M | - | 2.09 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
193 M | 223 M | - | 225 M | 196 M | 181 M | 174 M | 181 M | 136 M | 109 M | 109 M | 109 M | 65.9 M | 63.1 M | 63.1 M | 63.1 M | 52.3 M | 49.5 M | 49.5 M | 49.5 M | 47.9 M | 46.9 M | 46.9 M | 46.9 M | 47.5 M | 49.6 M | 49.6 M | 49.6 M | 51.5 M | 51.1 M | 51.1 M | 51.1 M | 48.4 M | 48.9 M | 48.9 M | 48.9 M | 46.4 M | 46.9 M | 46.9 M | 46.9 M | 33 M | 40.2 M | 40.2 M | 40.2 M | 36.8 M | 38.1 M | 38.1 M | 38.1 M |
Total Assets |
457 M | 463 M | - | 472 M | 459 M | 450 M | 447 M | 450 M | 424 M | 405 M | 405 M | 405 M | 338 M | 325 M | 325 M | 325 M | 250 M | 251 M | 251 M | 251 M | 252 M | 250 M | 250 M | 250 M | 250 M | 252 M | 252 M | 252 M | 186 M | 183 M | 183 M | 183 M | 177 M | 177 M | 177 M | 177 M | 175 M | 177 M | 177 M | 177 M | 157 M | 161 M | 161 M | 161 M | 155 M | 155 M | 155 M | 155 M |
Cash and Cash Equivalents |
74.1 M | 81.5 M | - | 76.5 M | 72.7 M | 49.8 M | 70 M | 49.8 M | 63.2 M | 53.5 M | 53.5 M | 63.2 M | 68.6 M | 62.4 M | 62.4 M | 62.4 M | 61.5 M | 59.8 M | 59.8 M | 61.5 M | 54.7 M | 57.1 M | 57.1 M | 54.7 M | 49.3 M | 47.2 M | 47.2 M | 49.3 M | 53.4 M | 50 M | 50 M | 53.4 M | 49.5 M | 43 M | 43 M | 49.5 M | 43.7 M | 44.3 M | 44.3 M | 43.7 M | 33.1 M | 31.6 M | 31.6 M | 33.1 M | 26.2 M | 23.6 M | 23.6 M | 26.2 M |
Book Value |
457 M | 463 M | - | 472 M | 459 M | 450 M | 447 M | 450 M | 424 M | 405 M | 405 M | 405 M | 338 M | 325 M | 325 M | 325 M | 250 M | 251 M | 251 M | 251 M | 252 M | 250 M | 250 M | 250 M | 250 M | 252 M | 252 M | 252 M | 186 M | 183 M | 183 M | 183 M | 177 M | 177 M | 177 M | 177 M | 175 M | 177 M | 177 M | 177 M | 157 M | 161 M | 161 M | 161 M | 155 M | 155 M | 155 M | 155 M |
Total Shareholders Equity |
341 M | 368 M | - | 375 M | 345 M | 328 M | 322 M | 345 M | 279 M | 248 M | 279 M | 279 M | 197 M | 191 M | 197 M | 197 M | 179 M | 175 M | 179 M | 179 M | 173 M | 170 M | 170 M | 173 M | 166 M | 166 M | 166 M | 166 M | 169 M | 166 M | 166 M | 166 M | 161 M | 161 M | 161 M | 161 M | 157 M | 155 M | 155 M | 155 M | 138 M | 143 M | 143 M | 143 M | 138 M | 139 M | 139 M | 139 M |
All numbers in USD currency